| Sep 27 |
Firefly Neuroscience files to sell 2.56M shares for holders
|
| Sep 20 |
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
|
| Sep 10 |
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
|
| Sep 5 |
Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors
|
| Aug 26 |
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11
|
| Aug 22 |
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
|
| Aug 21 |
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
|
| Aug 13 |
UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
|
| Aug 13 |
Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
|
| Aug 12 |
Upcoming Stock Splits This Week (August 12 to August 16) – Stay Invested
|
